Belal Howidi
Expertise:
Belal Howidi is a Research Associate in the value and evidence division at EVERSANA with experience in literature reviews, manuscripts, RWE research, value dossiers, CADTH/INESSS submissions, and HEOR modelling.
Belal began his professional journey with EVERSANA in September 2022. Since then, Belal has been involved in various projects including targeted literature reviews, systematic literature reviews, value dossier development, and CADTH submissions, all of which cover a wide spectrum of disease spaces (e.g., Alzheimer’s disease, psoriasis, depression, breast cancer, and rare diseases such as transthyretin-mediated amyloidosis). More recently, Belal has been involved in medical writing and modelling development, such as budget-impact modelling and pharmacoeconomic adaptations for Canadian submissions.
Belal holds an MSc in Neuroscience from McGill University, and an Honours BSc Specialization in Psychology with a Major in Pharmacology from the University of Western Ontario.
Articles by Belal Howidi
Real-World Effectiveness of Treatments Post-CDK4/6i in Treating HR+/HER2- Locally Advanced or Metastatic Breast Cancer
Since the FDA’s approval of palbociclib plus letrozole in 2015, cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), in combination with endocrine therapy (ET), have become the standard of care for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced/metastatic breast cancer (HR+/HER2- LABC/mBC) in the first-line (1L) treatment setting. However, there is no clear standard […]